ArticleJoint diseases and related surgery2025
Hidden blood loss of percutaneous vertebroplasty in the treatment of spinal metastases of breast cancer.
Article in Joint diseases and related surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- OPTIModel scoring for metastatic bone tumors: A data-driven tool for surgical planning and prognosis.Joint diseases and related surgery · 2026Article
- Postoperative inflammatory markers are not associated with hidden blood loss after knee arthroscopy.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe aim of this study was to evaluate hidden blood loss (HBL) and to identify its possible risk factors after percutaneous vertebroplasty (PVP) in patients with spinal metastases from breast cancer. PATIENTS AND
methodsBetween January 2020 and January 2024, a total of 54 female patients (mean age: 65.3±7.9 years, range, 47 to 79 years) with breast cancer and vertebral metastases who underwent PVP were retrospectively analyzed. Patient data were collected including demographic characteristics, oncological profiles, laboratory parameters, particularly pre- and postoperative hematocrit (Hct) levels, and clinical variables. The Sehat equation was employed to quantify HBL based on Hct alterations. To identify significant predictors of HBL, a multiple linear regression analysis of potential risk factors was carried out.
resultsThe mean surgical time was 32.0±8.5 min. Cement leakage occurred in 44.4% of cases. The mean hemoglobin (Hb) loss and Hct loss were 0.9±0.4 g/dL and 2.8±0.6%, respectively. The mean HBL was 287.2±57.4 mL. Multiple linear regression analysis showed that HBL was positively correlated with bone metastasis (p=0.010), surgical time (p=0.009), number of punctures (p=0.036), cement leakage (p=0.026), Hct loss (p=0.020), and TBL (p<0.001), while it was negatively correlated with postoperative Hct (p=0.024).
conclusionBone metastasis, surgical time, number of punctures, cement leakage, Hct loss, and TBL are independent risk factors for HBL. Therefore, HBL warrants clinical attention in patients with spinal metastases from breast cancer undergoing PVP, particularly those with these risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.